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Immunization of newborn infants with standard measles vaccines is not effective because of the presence of maternal
antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles
virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication-
defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months
of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these
infants were compared to additional infants that had maternal measles-neutralizing antibody. In the absence of measles
antibody, vaccination with either vector induced neutralizing antibody, cytotoxic T cell (CTL) responses to measles virus and
protection from systemic measles infection and skin rash. The infants vaccinated with the MVA vector developed lower
measles-neutralizing antibody titers than those vaccinated with the WR vector, and they sustained a transient measles
viremia upon challenge. Either maternal antibody or passively transferred MIG blocked the humoral response to vaccination
with both WR and MVA, and the frequency of positive CTL responses was reduced. Despite this inhibition of vaccine-induced
immunity, there was a reduction in peak viral loads and skin rash after measles virus challenge in many of the infants with
preexisting measles antibody. Therefore, vaccination using recombinant vectors such as poxviruses may be able to prevent
nts.the severe disease that often accompanies measles in infa
INTRODUCTION
Measles virus (MV) is a negative-strand RNA virus in
the Morbillivirus genus of the family Paramyxoviridae,
and it is the causative agent of measles (Griffin and
Bellini, 1996). Measles is a highly contagious childhood
disease characterized by fever and respiratory and sys-
temic infection. Measles in the infant is frequently asso-
ciated with serious complications and a high mortality
rate. Measles cases have dropped dramatically world-
wide since the introduction of live, attenuated vaccines
in the 1960s, especially in the developed countries.
There were only 100 reported cases in the U.S. in 1999
(CDC, 2000), and the interruption of indigenous MV trans-
mission in the U.S. has been maintained since late 1993
(CDC, 1996; Watson et al., 1998). Although the currently
used live, attenuated measles vaccines are very safe
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and effective, they are neutralized in vivo by maternal
antibody (Albrecht et al., 1977). To avoid the interference
of maternal antibody, vaccine is administered at the age
of 9 months in developing countries and at 12–15 months
of age in the developed nations. The existence of a
window of susceptibility to infection, between the time of
decay of maternal antibody below a protective level and
the time of vaccination, contributes to a worldwide child-
hood measles mortality of 1,000,000 annually, mainly in
the developing countries (World Health Organization,
1996). Recently, several reports demonstrated that in-
fants even less than 4 months old can contract measles
(Oshitani et al., 1998; Wairagkar et al., 1998). The use of
high-titered or inactivated measles vaccines was found
to be unacceptable as a means to overcome the inter-
ference of maternal antibody (Aaby et al., 1988, 1993;
Fulginiti et al., 1967; Halsey, 1993; Kumar et al., 1998;
Whittle et al., 1988).
The two envelope glycoproteins of MV, the hemagglu-
tinin (H) and fusion (F) proteins, are important compo-
nents of a measles vaccine. During MV infection, the H
and F proteins elicit both neutralizing antibodies and
cellular immunity. Neutralizing antibodies prevent the
spread of extracellular virus and the cellular immune
response plays a critical role in the recovery from infec-
acciniation (Burnet, 1968; Good and Zak, 1956). CTL epitopes
have been mapped to H and F in a human population
(Jaye et al., 1998a,b). Thus, the expression of MV H and
F in a recombinant vector like vaccinia virus might be
able to circumvent the effect of maternal antibody and to
immunize the newborn host to H and F antigens.
Unlike rodents, Asian macaques contract measles
naturally or experimentally, and the clinical signs of
measles are similar to those in humans; thus, the
monkey is a practical model for the study of measles
pathogenesis and for the development of new measles
vaccines (Griffin and Bellini, 1996; Hall et al., 1971;
Kobune et al., 1996; McChesney et al., 1997; van Bin-
nendijk et al., 1994). Several studies have shown that
recombinant vaccinia viruses expressing the MV H
and F proteins can protect against MV infection in both
mice and monkeys (Drillien et al., 1988; van Binnendijk
et al., 1997; Wild et al., 1992). The highly attenuated
modified vaccinia Ankara (MVA) has been used as a
recombinant expression vector and is being devel-
oped as candidate vaccine for humans (Moss et al.,
1996). The aim of the present study was to compare
the immunogenicity and protective efficacy of two vac-
cinia viruses, the WR strain and MVA, which express
the measles H and F proteins, in infant monkeys in the
presence of neutralizing antibody. MV neutralizing an-
tibodies and CTL responses were measured after vac-
cination in the presence or absence of MV immune
globulin (MIG) or natural maternal antibody. Differing
FIG. 1. Experimental design: vaccination of infant macaques with v
absence of MIG or maternal antibody.
PREEXISTING ANTIBODYlevels of protection were observed after a respiratory-
mucosal challenge with wild-type MV.RESULTS
Experimental design and humoral immune responses
after vaccination
As shown in Fig. 1, infant monkeys were divided into
groups that received 0, 3.5, or 7 ml of MIG 48 h prior to
vaccination. At 48 h, the geometric mean neutralizing
antibody titer (GMT) in the blood was 160 in Group 4,
which received 3.5 ml MIG (range 80–320), and the GMT
was 452 in Group 5, which received 7 ml MIG (range
320–2560, Table 1). The GMTs achieved after adminis-
tration of MIG were similar to the GMT of 226 (range
80–2560) measured in eight monkeys with maternally
derived antibody (Table 2). At the same 48 h time point
(day of vaccination), sera from six monkeys that received
3.5 or 7 ml MIG were also measured by the conventional
plaque reduction neutralization method, and a GMT of
2466 was calculated (range 1393–3734). These titers are
in the range for human newborns with maternal antibody
(range 32–32,768; Sato et al., 1979).
The infant monkeys were vaccinated by the intrader-
mal (id) route with either WR H&F or WR b gal or by the
intranasal (i.n.) and intramuscular (im) routes with MVA
H&F or MVA control. Humoral immune responses to
vaccination were evaluated by virus neutralization and by
radio-immunoprecipitation (RIP) for antibodies to the H
and the nucleoprotein (N). Table 1 shows the titers of
neutralizing antibody to MV after vaccination with WR b
gal or WR H&F in the presence or absence of MIG. Very
recombinants expressing MV H and F proteins in the presence or
203MEASLES VACCINATIONANDlow levels of MV neutralizing antibody (titers of 10–20)
were detected in the two infants of Group 1 vaccinated
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ontrol infants in Group 2, the subcutaneous (sc) inocu-
ation of 7 ml MIG induced titers of 320 and 160 that
aned to an undetectable level at 20 weeks, the time of
hallenge. In contrast, these infant monkeys developed a
trong antibody response to vaccinia virus (data not
hown). In Group 3 monkeys vaccinated with WR H&F
ithout MIG, MV neutralizing antibody developed after
accination, and the monkeys had a high titer of antibody
t 20 weeks except for Monkey 30310, with a titer of 40.
nly two of five monkeys in this group had a rise in
ntibody titer after the boost at 8 weeks. Antibody to the
protein but not to the N protein, which was absent from
he vaccine, was detected by RIP (Fig. 2, Monkey 30989).
owever, in monkeys vaccinated in the presence of 3.5
r 7 ml MIG, Groups 4 and 5, neutralizing antibody titers
T
Neutralizing Antibody Titers to Measles Virus in Monkeys Immuniz
wksa
Reciprocal neutralizing
Group 1
(WR bgal)
Group 2
(WR bgal 1
MIG 7 ml)
Group 3
(WR H&F 1 PBS or NMS
30998b 31031 30999 31005 30305 30308 30989 31017
0 20 10 320 160 10 20 10 10
2 20 ,10 160 80 80 80 80 40
8 10 ,10 40 20 160 320 1280 160
10 ,10 ,10 20 10 160 640 1280 160
20 ,10 ,10 ,10 ,10 640 1280 1280 320
22c 1280 640 1280 320 5120 1280 2560 1280
a MIG, PBS, or NMS (normal monkey serum) was inoculated at 48
hallenged at Week 20.
b Monkey number.
c 2 weeks postchallenge.
T
Neutralizing Antibody Titers to Measles Virus in Monkeys Immunize
wksa
Reciprocal neutralizing an
Group 6
(With low/medium titer maternal
30985b 30992 31004
0 160 80 160
2 40 80 40
8 20 80 20
10 20 40 20
20 10 40 10
22c 1280 640 1280
a MIG or PBS was inoculated at 48 h prior to immunization at Week
204 ZHb Monkey number.
c 2 weeks postchallenge.aned over the vaccination period even after boosting.
his was also demonstrated by RIP (Fig. 2, Monkeys
0991 and 30997). MV neutralizing antibodies were not
etected or barely detected in these animals at 20
eeks, and there was no difference in antibody re-
ponse to vaccination between the monkeys receiving
.5 or 7 ml MIG. Also, infants that had maternal antibody
t the time of vaccination, either low to medium (Group 6)
r high titer (Group 7), had waning neutralizing titers in
he same ranges as those monkeys that received 3.5 or
ml MIG (Table 2).
Immunoprecipitation experiments confirmed the re-
ults of the neutralization assays (Fig. 2). In the monkeys
accinated with WR H&F in the absence of MIG, antibody
o H was easily detected by RIP on the day of challenge.
n contrast, the amount of H that could be precipitated by
h Recombinant Vaccinia (WR) in the Presence or Absence of MIG
y titer in immunized monkeys
Group 4
(WR H&F 1 3.5 ml MIG)
Group 5
(WR H&F 1 7 ml MIG)
30991 30990 31025 30997 31024 30327 30328 30330 30332
160 160 160 320 80 320 320 320 320
160 80 80 80 40 160 160 160 160
20 20 160 40 20 80 10 20 10
10 20 20 10 20 40 20 10 20
,10 10 20 10 20 10 20 20 40
640 320 1280 40 1280 640 1280 10 1280
to immunization at Week 0. Monkeys were boosted at 8 weeks and
Recombinant Vaccinia (WR) in the Presence of Maternal Antibody
iters in monkeys immunized with WR H&F
Group 7
(With high titer maternal Ab)
31026 30995 31000 31027
160 320 2560 320
80 160 320 160
40 10 40 40
10 10 20 10
10 10 ,10 10
640 320 40 640
keys were boosted at 8 weeks and challenged at Week 20.
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o that asera from monkeys that were vaccinated in the presence
of maternal antibody or MIG decreased over time and
little antibody to H was detectable on the day of chal-
lenge. Since N was not present in the vaccine, antibody
to N in the postchallenge sera provided an indicator for
replication of the challenge virus. In monkeys vaccinated
with WR H&F in the absence of MIG or maternal anti-
body, relatively little N was precipitated by the postchal-
lenge serum sample. Sera from monkeys vaccinated in
the presence of MIG or maternal antibody precipitated
large amounts of N due to replication of the challenge
virus (Fig. 2).
Table 3 shows the titers of neutralizing antibody to MV
after vaccination with recombinant MVA in the presence
of 0 or 7 ml MIG. In the MVA control monkeys (Groups 8
and 9), antibody titers were similar to those of WR b-gal-
vaccinated monkeys. No neutralizing antibody response
to MV was induced, a decay of transferred measles
antibody was observed, and there was little detectable
FIG. 2. Immunoprecipitation of MV H and N proteins by sera from va
30998 in Group 1 vaccinated with WR bgal, Monkey 30989/Group 3/W
1000/Group 7, and Monkey 31026/Group 6/WR H&F 1 maternal antib
and before administration of MIG), 2 weeks postboost, day of challeng
f H and N with monoclonal antibodies specific for each protein. Note
T
Neutralizing Antibody Titers to Measles Virus in Monkeys Immuniz
wksa
Reciprocal neutralizing
Group 8
(MVA)
Group 9
(MVA 1 7 ml MIG)
30270b 30277 30267 30269 30273
0 160 10 320 640 20
2 160 10 80 320 10
8 40 10 80 80 10
10 10 10 10 20 320
20 10 ,10 ,10 10 160
22c 640 2560 320 320 640
a MIG or PBS was inoculated at 48 h prior to immunization at Week
PREEXISTING ANTIBODYb Monkey number.
c 2 weeks postchallenge.neutralizing antibody at 20 weeks. In contrast, monkeys
vaccinated with MVA H&F in the absence of MIG (Group
10) developed MV-specific antibody after vaccination,
and the antibody titers increased after boosting in two of
four animals. All animals had a neutralizing antibody titer
$1:80 at 20 weeks (Table 3), although these titers were
lower in general than those of monkeys vaccinated with
WR H&F. A decline in neutralizing antibody titers was
demonstrated in monkeys that received 7 ml MIG before
MVA H&F vaccination in Group 11 with no response to
the booster vaccination.
In contrast to MV neutralizing antibody responses,
antibody responses to vaccinia virus were detected in all
animals that received MIG or PBS, whether by vaccina-
tion with WR or MVA (Table 4). Antibody titers to vaccinia
virus increased after boosting with MVA H&F, but these
titers returned to the levels before boosting, which were
similar to those of monkeys vaccinated with WR H&F. No
antibody response to MV was detected in Monkey 30330
ed monkeys. Six monkeys’ sera are shown by vaccine group: Monkey
Monkeys 30991 and 30997/Group 4/WR H&F 1 3.5 ml MIG, Monkey
ur lanes are shown for each monkey corresponding to prevaccination
4 weeks postchallenge. The last two lanes at right show precipitation
nonspecific band migrates with the N protein.
Recombinant Vaccinia (MVA) in the Presence or Absence of MIG
dy titers in immunized monkeys
oup 10
A H&F)
Group 11
(MVA H&F 1 7 ml MIG)
30281 30282 30319 30326 30297 30298
,10 ,10 640 2560 320 320
20 ,10 320 640 160 80
80 80 80 80 40 80
160 80 10 20 40 80
80 80 10 20 10 40
1280 5120 1280 1280 5120 5120
keys were boosted at 8 weeks and challenged at Week 20.
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cat 2 weeks after challenge (Table 1). All other animals
developed strong antibody responses to MV after chal-
lenge (Tables 1–3).
CTL responses to MV after vaccination in the
presence or absence of MIG
Peripheral blood mononuclear cells (PBMC) were col-
lected from all monkeys at Weeks 0, 8, 10, and 20 for the
T
Antibody Titers to Vaccinia Virus in Monkeys Immunized with Re
wksa
Reciprocal ELIS
Group 3
(WR H&F)
Group 5
(WR H&F 1 7ml MIG)
30305b 30308 30310 30327 30328 30330 3033
0 200 ,200 ,200 ,200 200 200 20
8 6400 12800 3200 6400 6400 1600 1280
10 6400 6400 6400 3200 6400 3200 640
20 3200 6400 6400 3200 6400 3200 640
a MIG, PBS, or NMS (normal monkey serum) was inoculated at 48
hallenged at Week 20.
b Monkey number.
206 ZHFIG. 3. MV-specific CTL responses in monkeys immunized with WR vaccini
immunization.study of MV-specific CTL activity. No CTL response to
MV was detected before vaccination, and there were no
detectable CTL responses to MV throughout the entire
vaccination period in monkeys vaccinated with WR b gal
or the MVA control (Groups 1, 2, 8, and 9, Figs. 3 and 4).
In Group 3 animals vaccinated with WR H&F without
MIG, three of five animals had CTL responses to MV at
8 weeks postvaccination, and five of five had MV-specific
nant Vaccinia (WR or MVA) in the Presence or Absence of MIG
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ANDCTL activity at 2 weeks postboost and at 20 weeks (Fig.
3, Table 5). In the monkeys that received 3.5 ml MIG
before vaccination with WR H&F (Group 4), three of five
developed CTL activity after vaccination and boosting,
and in the monkeys receiving 7 ml MIG before vaccina-
tion in Group 5, two of four developed CTL responses to
MV (Fig. 3, Table 5). Three of eight monkeys with mater-
nal antibody at the time of vaccination developed CTL
responses after vaccination or boosting (Groups 6 and 7,
Table 5). Monkeys vaccinated with MVA H&F had results
similar to those monkeys vaccinated with WR H&F. If the
animals were not given MIG before vaccination (Group
10, Fig. 4), four of four had CTL responses after vaccina-
tion and boosting, but only one of four monkeys in Group
11 had detectable CTL activity to MV after receiving MIG
(Fig. 4, Table 5).
Clinical signs and viral loads after MV-Davis
challenge
All the monkeys were inoculated i.n. with MV-Davis at
20 weeks after the first vaccination. All of the monkeys
vaccinated with WR b gal or the MVA control developed
kin rashes between Days 8 and 12 after MV challenge
Groups 1, 2, 8, and 9 and Table 5). However, monkeys
hat were vaccinated with WR H&F or MVA H&F after
eceiving 0 or 3.5 ml MIG (Groups 3, 4, and 10) remained
ealthy and no skin rashes were observed. Two of four
onkeys developed skin rashes after MV challenge in
roups 5 and 11, vaccinated with WR H&F or MVA H&F
fter receiving 7 ml MIG (Table 5). Three of eight mon-
FIG. 4. MV-specific CTL responses in monkeys immunized with MVA
vaccinia recombinants. The time point is Week 10, 2 weeks after the
second immunization.
PREEXISTING ANTIBODYeys in Groups 6 and 7 that had maternal antibody at the
ime of vaccination developed skin rashes after MV chal-
w
oenge (Table 5). Skin rashes correlated positively with
iral loads in PBMC on Days 7 or 14 after challenge and
egatively with CTL activity prior to challenge (see the
tatistical analysis below).
PBMC on Days 7, 14, and 28 after MV challenge were
ocultured with Raji cells to quantitate MV viremia. All
our WR b gal-vaccinated monkeys (with and without
IG, Groups 1 and 2) had a peak of viremia on Day 7,
hen the viral load declined on Day 14, and MV was not
etected on Day 28 (Fig. 5A). This viremia kinetics is
imilar to that of naive animals inoculated with measles
irus (Zhu et al., 1997). No viremia was detected in the
ive animals of Group 3 vaccinated with WR H&F without
IG (Fig. 5B); in Group 4, one of four monkeys vacci-
ated with WR H&F with 3.5 ml MIG had no detectable
irus in PBMC postchallenge (pc), and the other three
nfants had low and transient viremia on Day 7 (Fig. 5B).
n monkeys vaccinated with WR H&F in the presence of
ml MIG (Group 5), there was no detectable viremia pc
n Monkey 30330, which had a strong CTL response after
accination; the other three monkeys had high viral loads
hich were similar to those of WR b gal-vaccinated
onkeys (Fig. 5B). Thus a dose response to MIG was
uggested by the kinetics and peak of viral loads after
hallenge. The eight monkeys in Groups 6 and 7 with
aternal antibody at the time of vaccination had viral
oads that were similar to the monkeys vaccinated in the
resence of 3.5 or 7 ml MIG; five of eight had high viral
oads and only one monkey had no detectable viremia
fter MV challenge (Table 5).
In the MVA control monkeys of Groups 8 and 9, the
inetics of viremia pc were similar to those of the WR
b-gal monkeys (Fig. 6A). Vaccination with MVA H&F, in
the absence of MIG (Group 10), resulted in one of four
animals with no detectable viremia; the other three mon-
keys had transient viremia on Day 7 pc, which was 2
logs10 lower than that of the MVA controls (Fig. 6B). One
f four monkeys receiving 7 ml MIG before vaccination
ith MVA H&F (Group 11) had transient viremia on Day 7
c, and the other three monkeys had high viral loads
hich were similar to those of the MVA controls (Fig. 6B).
ummary analysis of data (Table 5)
Animals with preexisting antibody at the time of vac-
ination were significantly less likely to develop a de-
ectable CTL response (P 5 0.004) and neutralizing an-
ibody (P 5 0.0001) postimmunization, than animals hav-
ng no preexisting antibody. The postchallenge peak viral
oad was significantly reduced in animals having no
reexisting antibody at the time of vaccination compared
o those with low titers (P 5 0.0135) or high titers (P 5
.0002) of preexisting antibody. Although there was an
bvious overall trend toward increased peak viral load
207MEASLES VACCINATIONith increasing levels of preexisting antibody at the time
f vaccination, the difference in viral load between
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2groups with low and high titers of preexisting antibody
was not significant at the alpha 5 0.05 level (P 5 0.0942).
significant inverse relationship was found between the
resence of a prechallenge CTL response and postchal-
enge skin rash, both for all animals, regardless of pre-
hallenge neutralizing antibody status (P 5 0.0001) as
T
Summary of Immune Responses Prior to MV Ch
Experimental
group Vaccine 6 Ab
Monkey
No.
1
WR 2 bgal
1 PBS
30988
31031
2 1 7 ml MIG
30999
31005
3
WR H&F
1 PBS or NMS
30305
30308
30310
30989
31017
4 1 3.5ml MIG
30990
30991
30997
31024
31025
5 1 7ml MIG
30327
30328
30330
30332
6 1 low/medium-titer
maternal Ab
30985
30992
31004
31018
31026
7 1 high-titer
maternal Ab
30995
31000
31027
8
MVA
1 PBS
30270
30277
9 1 7ml MIG
30267
30269
10
MVA H&F
1 PBS
30273
30280
30281
30282
11 1 7ml MIG
30297
30298
30319
30326
a Neutralizing antibody titer on the day of challenge: (2) #20 recipr
b Measles-specific CTL response detected prior to challenge.
c Viral load after MV challenge: (2) not detected, (1) ,103 TCID50/1
(111) .103 TCID50/10
6 cells on Day 7 and .10 TCID50/10
6 cells on D
08 ZHell as for animals without prechallenge neutralizing
ntibody titers (P 5 0.001).
3
oThere were four infant monkeys that had neither neu-
ralizing antibody on the day of challenge nor a detect-
ble MV-specific CTL response prior to challenge that
ere still protected from high viral loads or skin rash
pon pathogenic virus challenge (Monkeys 31024 and
1025 in Group 4, Monkey 31000 in Group 7, and Monkey
and Viral Load and Skin Rash after Challenge
Neutralizing
antibodya CTLb
MV viral
loadc
Skin
rash
2 2 111 1
2 2 111 1
2 2 111 1
2 2 111 1
11 1 2 2
11 1 2 2
1 1 2 2
11 1 2 2
11 1 2 2
2 1 11 2
2 1 1 2
2 1 2 2
2 2 1 2
2 2 1 2
2 2 111 1
2 2 11 1
2 1 2 2
1 1 11 2
2 2 111 1
1 2 111 2
2 1 111 2
2 1 2 2
2 2 111 1
2 1 11 2
2 2 1 2
2 2 111 1
2 2 111 1
2 2 111 1
2 2 111 1
2 2 11 1
1 1 2 2
1 1 1 2
1 1 1 2
1 1 1 2
2 2 111 1
2 2 11 2
2 2 111 1
1 1 1 2
er, (1) .20 and #160, (11) .160.
on Day 7 after challenge, (11) #10 TCID50/10
6 cells on Day 14 and
L.ABLE 5
allenge
ocal tit
U ET A0298 in Group 11, Table 5). This suggests that there are
ther protective immune responses to MV that we did not
W
o
ANDmeasure and that they are operative in the presence of
maternal antibody. These immune responses could in-
clude antibody dependent cellular cytotoxicity, delayed
type hypersensitivity, or antiviral CTL or neutralizing an-
tibody below the level of detection.
DISCUSSION
The major observations obtained from this study are
(1) that both WR and MVA vaccinia vectors are safe in
newborn rhesus monkeys and that they can immunize
newborns to recombinant viral proteins with the induc-
tion of both neutralizing antibody and CTL responses, (2)
that either maternal or passively transferred MV neutral-
izing antibody effectively blocks the humoral response to
H and F expressed by vaccinia virus in a prime-boost
regimen, (3) that the frequency of CTL responses to MV
in infants is reduced by preexisting measles antibody,
and (4) that some level of protective immunity, probably a
cell-mediated response, prevents the measles skin rash
FIG. 5. MV viral loads after challenge in monkeys immunized with
R vaccinia recombinants. In the top graph, the TCID50 end-point titers
f MV are shown for monkeys that were immunized with control WR
bgal in the absence (closed symbols, Group 1) or presence of MIG
(open symbols, Group 2). In the bottom graph, viral titers are shown for
monkeys that were immunized with WR H&F in the presence of 7 ml
MIG (open symbols, 4 monkeys of Group 5) or 3.5 ml MIG (closed
symbols, 5 monkeys of Group 4). The five monkeys of Group 3 that did
not receive MIG had no detectable viremia and their data are not
shown. The symbol legends indicate individual monkeys in each group.
PREEXISTING ANTIBODYdespite the inhibitory effect of antibody at the time of
immunization. Direct comparisons of the WR and MVAstrains of vaccinia virus as vaccine vectors revealed
similar levels of humoral and cellular immunity in mice
(Ramirez et al., 2000; Sutter et al., 1994). However, in this
study, peak levels of MV neutralizing antibody were
lower in infant monkeys vaccinated with the MVA vector,
and MVA was unable to prevent viremia after challenge.
It should be noted that the WR strain of vaccinia is
moderately pathogenic in rhesus macaques and that the
MVA strain cannot replicate fully in mammalian cells. In
contrast to the results reported herein, in another recent
study, macaques vaccinated with the same recombinant
measles MVA in the presence of MV neutralizing anti-
body did respond to a booster vaccination at 1 month,
and these animals were protected from systemic infec-
tion 1 year after vaccination (Stittelaar et al., 2000). How-
ever, that study modeled the vaccination of 6- to 9-month-
old infants with lower levels of maternal antibody than
newborns (Sato et al., 1979) and with a more mature
immune system.
In infant monkeys with preexisting antibody, it is strik-
ing that the neutralizing antibody response was inhibited
after the booster immunization at 8 weeks when MIG or
maternal antibody had declined to low levels. In the
FIG. 6. MV viral loads after challenge in monkeys immunized with
MVA vaccinia recombinants. In the top graph, the TCID50 end-point
titers of MV are shown for the monkeys that were immunized with the
control MVA in the absence (closed symbols, Group 8) or the presence
of MIG (open symbols, Group 9). In the bottom graph, viral titers are
shown for monkeys that were immunized with MVA H&F in the absence
(closed symbols, Group 10) or the presence of MIG (open symbols,
209MEASLES VACCINATIONGroup 11). The symbol legends indicate individual monkeys in each
group.
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U ET Aabsence of MIG, a boosted neutralizing antibody re-
sponse was observed in some infants. Two of five infants
immunized with WR H&F (Table 1, Group 3) and two of
four infants immunized with MVA H&F (Table 3, Group 10)
had fourfold rises in antibody titer after the boost at 8
weeks. Other investigations have shown that systemic
immunity to vaccinia virus inhibits the response to a
novel recombinant viral protein delivered with a second-
ary vaccinia exposure (Belyakov et al., 1999; Cooney et
l., 1991; Rooney et al., 1988). In these reports, vaccinia
ecombinants were neutralized immediately after inocu-
ation, and the effectiveness of the vaccine was reduced,
ut this rapid neutralization could be overcome by inoc-
lating the virus by a mucosal route (Belyakov et al.,
999). Preexisting vaccinia immunity inhibited both hu-
oral and cellular responses to recombinant antigens
Belyakov et al., 1999). In the present study, antibody
esponses to the vaccinia vector were not boosted at 8
eeks in infants immunized with WR (Groups 3 and 5,
able 4), but there was a large booster response to the
VA vector (Groups 10 and 11, Table 4). This difference
ay be due to the abortive infection by MVA or to the fact
hat MVA-immunized infants were inoculated by both a
arenteral and a mucosal route.
Maternally acquired antibodies are important in the
rotection of infants from disease in the first few months
f life, but the presence of maternal antibodies at the
ime of vaccination interferes with responses to several
nfant vaccines, such as for measles, parainfluenza, and
espiratory syncytial viruses (Durbin et al., 1999; Halsey
t al., 1985; Siegrist et al., 1998b). We hypothesized that
he chimeric expression of measles H and F in a vaccinia
ector could overcome the inhibition by maternal anti-
ody, which we proposed was due to viral neutralization.
ndeed, the pool of MIG that we used did not neutralize
he WR H&F vector in a vaccinia neutralization assay
data not shown), and it is unlikely that MV H and F
lycoproteins are expressed on the surface of this re-
ombinant vaccinia virion. Contrary to our hypothesis,
reexisting MV antibody reduced the humoral and cellu-
ar immune responses to measles H and F antigens
xpressed by vaccinia virus in vivo. Several similar ob-
ervations from mice, monkeys, and humans have been
eported for MV (Halsey et al., 1985; Kumar et al., 1998;
iegrist et al., 1998a; van Binnendijk et al., 1997) and
ther paramyxoviruses (Durbin et al., 1999; Murphy et al.,
988). This blockade, more effective against the priming
f B cells than of T cells, may be due to immune complex
ormation at the site of vaccinia replication and the sub-
equent degradation of antibody-complexed H and F
roteins by tissue macrophages. Alternatively, MV anti-
ody might downregulate the expression of the H and F
t the cell surface (Fujinami and Oldstone, 1979).
The MIG pool that was used in the present experiment
210 ZHas serum proteins other than immunoglobulins that may
ave influenced the outcome of vaccination. And themmunoglobulin components of MIG and maternally ac-
uired antibody are not the same; IgG1 and IgG3 have
igh-affinity receptors in the placenta, and they are pref-
rentially transferred to the fetus (McNabb et al., 1976).
ight infant monkeys with low- to high-titer maternal
ntibodies (average neutralizing antibody titer of 160)
ere vaccinated with WR H&F, and no detectable MV-
pecific humoral responses were induced. CTL re-
ponses were detected in three of these eight monkeys,
imilar to the number of monkeys vaccinated with WR
&F after receiving 3.5 or 7 ml MIG. Thus, at the levels
f immune response, viremia after pathogenic virus chal-
enge and clinical disease, MIG closely mimicked natural
aternal antibody. Further, there was no inhibitory effect
n immune responses to vaccination by a pool of normal
onkey sera that was measles seronegative (2 infant
onkeys in Group 3, Table 1).
In these experiments, infant monkeys (1–2 weeks old)
ere immunocompetent: they developed both humoral
nd cellular immunity after vaccination, but we do not
ave data from juvenile or adult monkeys to compare
mmune responses quantitatively. Recently, Gans et al.
eported that 6-month-old human infants have a defi-
iency in the humoral immune response but not in a
ellular immune response to measles vaccination by
omparison with 9- or 12-month-old infants (Gans et al.,
998). Similar observations were made for respiratory
yncytial virus infection of infants (Murphy et al., 1986).
ut immaturity of the infant immune system, particularly
t the humoral level, would not preclude successful im-
unization of newborns against viral pathogens like MV.
n this study, the inhibition of humoral responses by
reexisting antibody did not preclude protection from the
easles skin rash.
Although neutralizing antibody is a reliable sign of
accine-induced immunity, cellular immunity is also es-
ential to recovery from measles (Jaye et al., 1998a).
hildren with congenital agammaglobulinemia that con-
ract measles develop protective immunity without de-
ectable antibody after infection (Good and Zak, 1956).
ecently, it was shown that vaccinated children with no
etectable antibody response are protected from mea-
les and it was suggested that these children may have
ellular immunity that provides the protection (Carson et
l., 1995; Samb et al., 1995). Although antibody re-
ponses to H and F were undetectable in the vaccinated
onkeys receiving MIG, by either neutralization assay or
y RIP, some of these monkeys developed CTL re-
ponses to MV. There are several similar observations
oth in monkeys and in mice (Siegrist et al., 1998b; van
Binnendijk et al., 1997). In these reports, antibody re-
sponses were inhibited, but cellular immunity was not or
only partially inhibited. And those monkeys that devel-
oped cellular immunity without humoral immunity after
L.vaccination had very low cell-associated viremia after
challenge with wild-type virus (van Binnendijk et al.,
o
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AND1994). As recently proposed (Seiler et al., 1998), the
present results demonstrate that even though infant vac-
cines given in the presence of maternal antibody may not
be able to induce a detectable antibody response or to
prevent viral replication, they may stimulate a cellular
response capable of clearing infection and preventing
severe disease.
MATERIALS AND METHODS
Construction of WR and MVA recombinant vaccinia
viruses expressing MV H and F proteins
A recombinant WR strain of vaccinia virus expressing
both the H and F proteins of the Edmonston strain of MV
(WR H&F) was constructed as previously described
(Tamin et al., 1994). In this recombinant virus, H was
inserted into the TK gene under the control of the P7.5
promoter and F was inserted into the vaccinia HA gene
and expressed using the M1 promoter. Construction of
MVA H&F, a double-recombinant expressing the H and F
of the Edmonston strain of MV, was described elsewhere
(Stittelaar et al., 2000). Briefly, the H and F genes were
placed under control of the modified H5 and P7.5 pro-
moters, respectively, and inserted into deletions II and III
of the MVA genome, respectively. Both MVA and MVA
H&F were propagated in chicken embryo fibroblasts as
described (Sutter et al., 1994).
Passive transfer of MIG prior to vaccination
MIG is a pool of heated-inactivated sera from monkeys
that contracted measles during an outbreak amongst
juvenile monkeys at the California Regional Primate Re-
search Center in 1995. The reciprocal neutralizing anti-
body titer of MIG is 5120 by 50% end-point titration. MIG
(3.5 or 7 ml) was administered to infant rhesus monkeys
by SC inoculation 48 h prior to vaccination. Control infant
monkeys were inoculated sc with either 7 ml of phos-
phate-buffered saline (PBS) or pooled, heat-inactivated
normal monkey sera (NMS) that was negative for mea-
sles antibody by IgG ELISA (Zhu et al., 1997).
Vaccination with WR and MVA recombinant viruses
Colony-bred male and female newborn rhesus ma-
caques (Macaca mulatta), seronegative for simian type D
retroviruses, simian T-cell lymphotropic virus, and simian
immunodeficiency virus, were housed in accordance
with the American Association for Accreditation of Lab-
oratory Animal Care. This macaque colony is routinely
vaccinated against measles (Attenuvax, Merck and Co.,
Inc., Westpoint, PA), and ;25% of newborn monkeys
have maternal measles-neutralizing antibody. The inves-
tigators adhered to the guidelines of the Committee on
Care and Use of Laboratory Animals, National Re-
PREEXISTING ANTIBODYsources Council. Infant monkeys (1–2 weeks old, body
weight ;0.5 kg), after assaying for measles-neutralizing
o
lantibody, were vaccinated with either recombinant WR or
MVA (Fig. 1). In the WR groups, all animals were vacci-
nated id with 1 3 106 plaque-forming units (pfu), an
ptimal route and dose for this virus in infant monkeys
M. McChesney, unpublished data). As shown in Fig. 1,
our control monkeys were vaccinated with WR express-
ng beta galactosidase (WR-b gal) in the presence of 7 ml
IG (n 5 2) or PBS (n 5 2). Fourteen infants were
vaccinated with WR H&F in the presence of PBS (n 5 3)
or NMS (n 5 2), 3.5 ml (n 5 5) or 7 ml MIG (n 5 4).
Another eight infant monkeys that had maternal antibody
at a low to moderate neutralizing titer (80–160, n 5 5) or
a high titer (320–2560, n 5 3) were vaccinated with WR
H&F. In the MVA groups, all monkeys were vaccinated
with 1 3 108 pfus by both the im and i.n. routes. Four
ontrol monkeys were vaccinated with parental MVA in
he presence of 7 ml MIG (n 5 2) or PBS (n 5 2). Eight
nfants were vaccinated with MVA H&F in the presence
f 7 ml PBS (n 5 4) or 7 ml MIG (n 5 4, Fig. 1). All of the
nimals were boosted with the same recombinant vi-
uses and doses at 8 weeks after the first vaccination,
ut MIG was only administered before the first vaccina-
ion.
easurements of MV neutralizing antibodies and
ntibodies to H and N proteins by radio-
mmunoprecipitation (RIP)
MV neutralizing antibody was measured by viral anti-
en reduction in Vero cells in 96-well plates as described
reviously (Zhu et al., 1997). Neutralizing antibody titers
ere calculated as the highest dilution showing 50%
eduction in optical density of six control wells that con-
ained virus without serum. Selected sera were also
ested for viral neutralization by the plaque reduction
ethod (Albrecht et al., 1981). Antibodies to measles H
nd N proteins were detected by RIP as previously de-
cribed (Tamin et al., 1994), with a single exception. The
nfected-cell pellet was resuspended in RIP buffer (1%
odium deoxycholate, 1% Triton X-100, 0.2% SDS, 150
M NaCl, and 50 mM Tris–HCl at pH 7.4).
easurement of MV-specific CTL
PBMC were isolated from heparinized blood and cryo-
reserved in liquid nitrogen until use. To measure mea-
les CTL responses, PBMC were re-stimulated in vitro
ith MV antigen, followed by a 4-h chromium release
ssay as previously described (Zhu et al., 1997). The lysis
f mock-infected and measles virus-infected autologous
cell lines was measured and the percent specific lysis
as calculated as: 100 3 [(experimental release 2 spon-
aneous release)/(maximal release 2 spontaneous re-
ease)]. Specific lysis was considered positive if the lysis
211MEASLES VACCINATIONf infected targets was greater than twofold above the
ysis of mock-infected targets and if it was $10%.
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U ET AMeasurement of antibodies to vaccinia virus by
ELISA
Vaccinia virus antibodies were measured in plasma
samples from immunized animals as previously de-
scribed (Hirsch et al., 1996) with the following modifica-
tions. PBS containing 5% milk and 0.5% Tween 20 was
used for blocking. The substrate, BM Blue POD (Boeh-
ringer–Mannheim) was used according to the manufac-
turer’s instructions.
Challenge with pathogenic MV: clinical signs and MV
viral load
At 12 weeks after boosting, the monkeys were chal-
lenged by i.n. inoculation of 104.2 tissue culture infectious
oses 50% (TCID50) of the Davis 87 isolate of measles
virus grown in rhesus PBMC (McChesney et al., 1997).
The animals were monitored daily for anorexia, depres-
sion, coughing, dysentary, and skin rash. They were bled
on Days 7, 14, and 28 pc. Quantitation of viral load in
PBMC by end-point dilution coculture with Raji cells was
performed as previously described (Zhu et al., 1997). The
cultures were monitored for cytopathic effect and scored
by an indirect immunofluorescence assay using the KK2-
mAb to measles N protein (Bellini et al., 1986). The viral
titer was expressed as the TCID50 per 10
6 cells using the
ethod of Reed and Muench (1938).
tatistical analysis
For purposes of analysis, CTL response, antibody sta-
us, and skin rash were considered as dichotomous
ariables. Fisher’s exact probability test was used to
nalyze the relationship between antibody status at the
ime of vaccination and postimmunization CTL and neu-
ralizing antibody responses and the relationship be-
ween prechallenge CTL response, with or without neu-
ralizing antibody, on postchallenge skin-rash develop-
ent. Differences in postchallenge peak virus load
mong animals with no, low, or high preexisting antibody
natural maternal or MIG) at the time of vaccination were
nalyzed using the Kruskal-Wallis one-way ANOVA by
anks. Post hoc comparisons were performed using the
ilcoxin-Mann-Whitney test.
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